Multivariate analysis of the effects of study drug, type of allograft donor, source of stem cell graft, and type of CMV detection test used on the primary efficacy endpoint (occurrence of CMV disease or death from any cause) in the first 180 days after allogeneic SCT
| Variables . | Odds ratio . | Confidence interval . | P . |
|---|---|---|---|
| Foscarnet vs ganciclovir | 0.74 | 0.40 -1.34 | .32 |
| Unrelated vs related graft donor | 0.88 | 0.43 -1.80 | .73 |
| Bone marrow vs peripheral blood SCT | 0.96 | 0.48 -1.91 | .92 |
| PCR for CMV vs CMV antigenemia | 1.60 | 0.84 -3.03 | .14 |
| Variables . | Odds ratio . | Confidence interval . | P . |
|---|---|---|---|
| Foscarnet vs ganciclovir | 0.74 | 0.40 -1.34 | .32 |
| Unrelated vs related graft donor | 0.88 | 0.43 -1.80 | .73 |
| Bone marrow vs peripheral blood SCT | 0.96 | 0.48 -1.91 | .92 |
| PCR for CMV vs CMV antigenemia | 1.60 | 0.84 -3.03 | .14 |
CMV indicates cytomegalovirus; SCT, stem cell transplantation; PCR, polymerase chain reaction.